NextCure, Inc. (NXTC)
Oxford Ledge is still expanding full research coverage of NXTC. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
NextCure develops antibody-drug conjugates targeting validated cancer antigens in Phase 1 clinical trials.
SEC filings
- 8-K Entry into material agreement; Costs for exit or disposal activities; 5.01; Departure/election of directors or officers; Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-07-14
- 8-K Departure/election of directors or officers; Shareholder vote results; Financial statements and exhibits 2026-06-25
- 8-K Regulation FD disclosure; Other material event; Financial statements and exhibits 2026-06-01
- 10-Q Quarterly financial report (unaudited) 2026-05-07
- 8-K Results of operations / financial condition; Financial statements and exhibits 2026-05-07
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for NXTC. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open NXTC in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.